Preliminary Efficacy and Safety Results from RC48-C017: A Phase II Study of Neoadjuvant Treatment with Disitamab Vedotin Plus Toripalimab in Patients with Muscle Invasive Bladder Cancer (MIBC) with HER2 Expression.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined